Manipal Super Specialty Hospital and Stempeutics Research come together to offer Vijayawada`s first Stem Cell Therapy
Released on: September 26, 2008, 2:51 am
Press Release Author: Brand-Comm
Industry: Healthcare
Press Release Summary: Manipal Super Specialty Hospital, a leading Healthcare provider in Andhra Pradesh has tied up with Stempeutics Research, a leading stem cell company in India, to promote stem cell therapy in Andhra Pradesh.
Press Release Body: Manipal Super Specialty Hospital, a leading Healthcare provider in Andhra Pradesh has tied up with Stempeutics Research, a leading stem cell company in India, to promote stem cell therapy in Andhra Pradesh. The Global market for Stem Cell therapies is expected to be US$20 billion by 2010 and is expected to grow rapidly. Stem cell based products have already been released in the USA. In India, the expected market for stem cell therapy is approx US$ 540 million. Initially MSSH will conduct pilot studies for Parkinson’s Diseases, Spinal Cord Injury, Critical Limb Ischemia and Dilated Cardio Myopathy. Later on more diseases will be added based on Hospital requirements. Stem cell research offers unprecedented opportunities for developing new medical therapies for debilitating diseases. Medical and scientific interest in stem cells is based on a desire to find a source of new, healthy tissue to treat diseased or injured human organs. It is known that some organs, such as the skin and the liver, are adept at regenerating themselves when damaged. Recent research suggests that stem cells are a key to these regenerative properties. Stem Cells would be a major branch of Medical treatments and would be a standard of cure and practice in the years to come. Regenerative medicine is a rapidly emerging area of biomedical research with enormous therapeutic potential, and this would be an ideal supplement for existing medical treatments.
Speaking about the tie-up, Mr T. Ramoji, Vice President, Manipal Health Systems, said “Stem Cell therapy is showing promising results for various diseases and is currently used where conventional therapies could not cure a disease. Keeping in mind the overall disease burden of various medical conditions and the potential for stem cell therapy globally, MSSH has taken this new initiative of bringing stem cell therapy to Andhra Pradesh in collaboration with Stempeutics. With the expertise of the Clinicians at MSSH and stem cells expertise of Stempeutics, we will stand to gain and realize the clinical value of stem cells”.
Dr. Prabhakara Rao, Medical Director, MSSH added “We are happy about Stempeutics’ commitment in developing Andhra Pradesh as one of the Stem Cell Research and Therapy hubs. Our aim is to provide hope to patients suffering from life threatening diseases for which there is no cure. I have seen the world-class facility Stempeutics has created in Bangalore for stem cell isolation & up scaling and the world-class research on adult stem cells and human embryonic stem cells. I am convinced that this collaboration with Stempeutics will go a long way in establishing Vijayawada as a leading stem cell therapy hub”.
Speaking at the press conference, Mr B. N. Manohar, President, Stempeutics Research said, “While the initial foray of Stempeutics is in bone marrow derived mesenchymal stem cells, Stempeutics is investing heavily on its R&D to bring out some innovative products (like tailor made progenitor cells) in the near future based on adult stem cells. Stempeutics will leverage the experience gained so far in stem cell therapy for giving the best treatment to the patients in Andhra Pradesh. There will be continuous research for each disease so as to improve product development for effective therapy. Research will be conducted on effective cell number, route of transplantation etc. Further research will be carried out to develop lineage specific cells or precursor cells for more effective therapy”.
MSSH & Stempeutics are committed to delivering safe and effective stem cell therapies to patients. The partnership will focus on developing Vijayawada as the leading Stem Cell Therapy hub. The partnership will also develop health tourism by attracting international patients. Initial treatment will be based on bone marrow derived (autologous - derived from the patient) human mesenchymal stem cells. Human mesenchymal stem cells are 100% safe and have potential to treat various degenerative diseases. Stempeutics has treated more than 100 patients covering various diseases in India. Stempeutics has unrivalled experience and one of the most accomplished teams of stem cell researchers in basic science and clinical applications of innovative modalities. It has a proprietary and patented technology and procedure for mesenchymal stem cells isolation and large scale culture.
2022
